Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03756883 · ClinicalTrials.gov registry record · Phase 3
Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 999
- Enrollment target
NCT03756883 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 999 participants.
The verdict
NCT03756883, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 999 participants
- Enrollment target
Study Summary
A randomized, multiple-dose, blinded, placebo-controlled, parallel-group, multiple-center bioequivalence study with pharmacodynamic endpoints
Interventions
- DRUG Placebo Inhalation Powder
- DRUG Fluticasone Propionate and Salmeterol Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 999 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2019-11-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03756883
The ClinicalTrials.gov registry entry for NCT03756883 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 999 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Inhalation Powder is the first listed.
NCT03756883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03756883 about?
NCT03756883 is a clinical study titled "Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma". A randomized, multiple-dose, blinded, placebo-controlled, parallel-group, multiple-center bioequivalence study with pharmacodynamic endpoints
What is the current status of trial NCT03756883?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 999 participants. The study started on 2018-12-03. Estimated completion is 2019-11-10.
What interventions are being tested in trial NCT03756883?
The interventions under investigation include: Placebo Inhalation Powder (DRUG), Fluticasone Propionate and Salmeterol Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT03756883?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.